BeiGene Ltd (BGNE)
194.56
+0.30
(+0.15%)
USD |
NASDAQ |
Nov 21, 16:00
194.76
+0.20
(+0.10%)
After-Hours: 20:00
BeiGene Revenue (Quarterly): 1.002B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.002B |
| June 30, 2024 | 929.17M |
| March 31, 2024 | 751.65M |
| December 31, 2023 | 634.41M |
| September 30, 2023 | 781.31M |
| June 30, 2023 | 595.26M |
| March 31, 2023 | 447.80M |
| December 31, 2022 | 380.10M |
| September 30, 2022 | 387.63M |
| June 30, 2022 | 341.57M |
| March 31, 2022 | 306.63M |
| December 31, 2021 | 213.98M |
| September 30, 2021 | 206.44M |
| June 30, 2021 | 149.99M |
| March 31, 2021 | 605.87M |
| December 31, 2020 | 100.10M |
| September 30, 2020 | 91.08M |
| June 30, 2020 | 65.64M |
| March 31, 2020 | 52.06M |
| December 31, 2019 | 56.89M |
| September 30, 2019 | 50.14M |
| Date | Value |
|---|---|
| June 30, 2019 | 243.35M |
| March 31, 2019 | 77.83M |
| December 31, 2018 | 58.67M |
| September 30, 2018 | 54.20M |
| June 30, 2018 | 52.80M |
| March 31, 2018 | 32.54M |
| December 31, 2017 | 18.17M |
| September 30, 2017 | 220.21M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.393M |
| March 31, 2016 | 0.677M |
| December 31, 2015 | 4.677M |
| September 30, 2015 | 1.38M |
| June 30, 2015 | 1.38M |
| March 31, 2015 | 1.379M |
| December 31, 2014 | 1.381M |
| September 30, 2014 | 6.496M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
52.06M
Minimum
Mar 2020
1.002B
Maximum
Sep 2024
404.96M
Average
360.83M
Median
Revenue (Quarterly) Benchmarks
| Theravance Biopharma Inc | 16.87M |
| Merck & Co Inc | 16.66B |
| Bristol-Myers Squibb Co | 11.89B |
| Zai Lab Ltd | 102.26M |
| Halozyme Therapeutics Inc | 290.08M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -121.35M |
| Total Expenses (Quarterly) | 1.122B |
| EPS Diluted (Quarterly) | -1.17 |
| Enterprise Value | 19.09B |
| Gross Profit Margin (Quarterly) | 82.98% |
| Profit Margin (Quarterly) | -12.12% |
| Earnings Yield | -4.28% |
| Normalized Earnings Yield | -4.276 |